110
Participants
Start Date
September 9, 2019
Primary Completion Date
October 7, 2021
Study Completion Date
October 7, 2021
Cabozantinib group
The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
Hospices Civils de Lyon - Hôpital de la Croix Rousse, Lyon
CHU Amiens Picardie - Hôpital Sud, Amiens
CHU Jean Minjoz, Besançon
Hôpital Avicenne, Bobigny
Centre Hospitalier de Boulogne sur mer, Boulogne-sur-Mer
Centre hospitalier universitaire Côte de nacre, Caen
Hôpital Beaujon, Clichy
CHRU de Lille-Hôpital Claude Huriez, Lille
CHU Dupuytren, Limoges
APHM - Timone, Marseille
Centre Hospitalier Universitaire de Montpellier, Montpellier
APHP - Hôpital St Antoine, Paris
Hôpital haut- lévêque, Pessac
Hôpital Robert Debré - CHU de Reims, Reims
CHRU Rennes site pontchaillou, Rennes
CHU de St Etienne, Saint-Priest-en-Jarez
CHU Toulouse PURPAN, Toulouse
Hôpital Brabois adulte - CHU de Nancy, Vandœuvre-lès-Nancy
Hospices Civils de Lyon
OTHER